Urinary Bladder, Overactive: Clinical Trials

73 trials for Urinary Bladder, Overactive, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

73 completed. 73 Phase 3, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 373Completed 73
Phase 23Completed 3

Follow Urinary Bladder, Overactive: new trials by email Literature Review of Urinary Bladder, Overactive trials Research Report on Urinary Bladder, Overactive

Trials (filtered) newest first · largest first

All 73 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder
DA-8010 Placebo, DA-8010 2.5mg, DA-8010 5mg - Overactive Bladder
Phase 3CompletedDong-A ST Co., Ltd.6072022-05-122024-06-26
To Evaluate the Efficacy and Safety of JLP-2002 on Symptoms of Overactive Bladder
JLP-2002 A mg, Placebo - Overactive Bladder
Phase 3CompletedJeil Pharmaceutical Co., Ltd.2102020-05-212022-01-28
Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia
Vibegron - Overactive Bladder
Phase 3CompletedUrovant Sciences GmbH2762019-09-192024-08-21
Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
Vibegron, Placebo - Overactive Bladder
Phase 3CompletedUrovant Sciences GmbH11052019-03-262024-08-07
An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).
Vibegron, placebos, Tolterodine Tartrate ER - Overactive Bladder
Phase 3CompletedUrovant Sciences GmbH5062018-06-142021-03-18
A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)
vibegron, Vibegron placebo, Tolterodine Tartrate ER - Overactive Bladder
Phase 3CompletedUrovant Sciences GmbH15302018-03-262021-03-04
Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease
solifenacin, Pelvic floor muscle exercise-based behavioral therapy - Overactive Bladder, Parkinson Disease
Phase 3CompletedVA Office of Research and Development772018-03-012024-09-24
Efficacy and Safety Study of GSK1358820 in Japanese Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity
GSK1358820, Placebo - Urinary Bladder, Overactive
Phase 3CompletedGlaxoSmithKline212016-10-112021-07-14
Efficacy and Safety of GSK1358820 in Subjects With Overactive Bladder
GSK1358820, Placebo, Antibiotic therapy - Urinary Bladder, Overactive
Phase 3CompletedGlaxoSmithKline2502016-08-102020-11-27
Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Treatment of Overactive Bladder.
Uritos®, Urotol® - Overactive Bladder
Phase 3CompletedR-Pharm3002016-07-182019-05-21
Extension Study of Fesoterodine for Overactive Bladder Syndrome in Children.
Fesoterodine - Overactive Bladder
Phase 3CompletedStéphane Bolduc262015-10-012019-07-30
Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan
Mirabegron 25mg - Urinary Incontinence, Overactive Bladder Syndrome
Phase 3CompletedBuddhist Tzu Chi General Hospital1682015-04-282017-02-23
Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With OAB
THVD-201, Placebo(For THVD-201), Detrusitol 2mg tablet - Overactive Bladder
Phase 3CompletedSK Chemicals Co., Ltd.3842015-01-012017-01-12
Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children
Fesoterodine, Oxybutynin XL - Overactive Bladder
Phase 3CompletedStéphane Bolduc622014-12-012019-07-30
Efficacy of Darifenacin and Physiotherapy for the Treatment of Overactive Bladder in Women
Darifenacin, Physiotherapy - Overactive Bladder
Phase 3CompletedUniversidad de Valparaiso802014-05-012016-05-02
A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder
Solifenacin succinate, Mirabegron, Placebo to match solifenacin - Urinary Bladder Overactive, Overactive Bladder
Phase 3CompletedAstellas Pharma Europe B.V.18292014-03-172024-10-31
This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder
Solifenacin succinate, Mirabegron, Placebo to match solifenacin succinate - Urinary Bladder Overactive, Urinary Bladder Diseases\Urologic Diseases
Phase 3CompletedAstellas Pharma Europe B.V.35272013-11-052024-10-31
A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)
mirabegron 25 mg, mirabegron 50 mg, solifenacin 5 mg - Urinary Bladder Diseases, Urinary Bladder Overactive
Phase 3CompletedAstellas Pharma Europe Ltd.21742013-07-102024-10-31
Add-on Mirabegron in Pediatric Patients With Refractory Overactive Bladder
Mirabegron - Overactive Bladder, Urinary Incontinence
Phase 3CompletedCHU de Quebec-Universite Laval352013-04-012018-04-24
Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder
mirabegron - Overactive Bladder, Urinary Incontinence
Phase 3CompletedCHU de Quebec-Universite Laval582013-04-012018-06-20

Showing 20 of 73. Sign in to see all of them.

Narrower conditions

Urinary Incontinence (23)  ·  Urinary Incontinence, Urge (13)  ·  Urologic Diseases (5)  ·  Lower Urinary Tract Symptoms (4)  ·  Nocturia (4)  ·  Prostatic Hyperplasia (2)  ·  Urinary Bladder Diseases (2)  ·  Male Urogenital Diseases (1)  ·  Multiple Sclerosis (1)  ·  Parkinson Disease (1)  ·  Syndrome (1)  ·  Urinary Bladder, Neurogenic (1)

Broader conditions

Female Urogenital Diseases (73)  ·  Female Urogenital Diseases and Pregnancy Complications (73)  ·  Pathological Conditions, Signs and Symptoms (73)  ·  Signs and Symptoms (73)  ·  Urogenital Diseases (73)  ·  Urological Manifestations (73)  ·  Male Urogenital Diseases (72)  ·  Urinary Bladder Diseases (71)  ·  Lower Urinary Tract Symptoms (69)  ·  Urologic Diseases (68)  ·  Urination Disorders (30)  ·  Urinary Incontinence (7)  ·  Nervous System Diseases (3)  ·  Genital Diseases (2)  ·  Genital Diseases, Male (2)

Interventions

Solifenacin Succinate (18)  ·  Tolterodine Tartrate (16)  ·  mirabegron (14)  ·  Botulinum Toxins, Type A (9)  ·  fesoterodine (8)  ·  Saline Solution (5)  ·  N-(4-((5-(hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamide (4)  ·  propiverine (4)  ·  darifenacin (3)  ·  imidafenacin (3)  ·  oxybutynin (3)  ·  Anti-Infective Agents (1)  ·  Behavior Therapy (1)  ·  DA-8010 (1)  ·  Drug Therapy (1)

Sponsors

Astellas Pharma Inc (14)  ·  Allergan (7)  ·  Pfizer (7)  ·  Astellas Pharma Europe B.V. (4)  ·  Urovant Sciences GmbH (4)  ·  APOGEPHA Arzneimittel GmbH (2)  ·  Astellas Pharma Europe Ltd. (2)  ·  CHU de Quebec-Universite Laval (2)  ·  Duramed Research (2)  ·  GlaxoSmithKline (2)  ·  Novartis (2)  ·  Ono Pharmaceutical Co., Ltd. (2)  ·  Stéphane Bolduc (2)  ·  Bayer (1)  ·  Boston Scientific Corporation (1)

Countries

United States (40)  ·  Canada (21)  ·  Poland (20)  ·  Belgium (18)  ·  Germany (18)  ·  United Kingdom (17)  ·  Czechia (16)  ·  Russia (15)  ·  Spain (14)  ·  Hungary (13)  ·  Slovakia (13)  ·  South Korea (13)  ·  Ukraine (13)  ·  Italy (12)  ·  Sweden (12)

Top investigators

Alexis Te (1)  ·  Anthony Visco, MD (1)  ·  Benjamin Li, PhD (1)  ·  Cris Constantinescu, MD PhD (1)  ·  Daniela Marschall-Kehrel, MD (1)

Results publications

PMID 37160401, PMID 24246044, PMID 35881009, PMID 21293089, PMID 24754838, PMID 25288099, PMID 26231052, PMID 37811598, PMID 18502028, PMID 18584946, PMID 18663723, PMID 19143854, PMID 19233423, PMID 19348029, PMID 20121659, PMID 20707767, PMID 20723260, PMID 20829244, PMID 21428726, PMID 21798658, PMID 22008247, PMID 22092152, PMID 22503020, PMID 22965657, PMID 23036134, PMID 23448285, PMID 23608668, PMID 23769122, PMID 23892704, PMID 26516810, PMID 26876327, PMID 26965560, PMID 27564385, PMID 27687820, PMID 28150436, PMID 28916436, PMID 29866467, PMID 31930360, PMID 32239291, PMID 32665528, PMID 33231929, PMID 33332699, PMID 33356445, PMID 33469832, PMID 33620895, PMID 34292493, PMID 34921665, PMID 35685566, PMID 36384907, PMID 37586052

NIH funding

2017 (2), 2018 (2), 2008 (1), R03AG042335 (1), U01HD041249 (1), U10HD041250 (1), U10HD041261 (1), U10HD041267 (1), U10HD054136 (1), U10HD054214 (1), U10HD054215 (1), U10HD054241 (1)